Najean Y, Mugnier P, Dresch C, Rain J D
Department of Nuclear Medicine and Haematology, Hôpital Saint-Louis, Paris, France.
Br J Haematol. 1987 Nov;67(3):285-91. doi: 10.1111/j.1365-2141.1987.tb02349.x.
Over 20 years, 58 cases of PV in young people (46 meeting the full PVSG criteria, 12 with elevated red cell volume and leucocytosis or thrombocytosis, without splenomegaly) were studied and have been followed for periods of 3-24 years. These cases represent approximately 5% of the cases of PV referred to the Department of Nuclear Medicine of St Louis Hospital during this period. They differ from older patients in the initial clinical severity, the short interval between the first symptoms and the diagnosis, frequent presentation with a life-threatening complication (two cases of hepatic vein thrombosis, six thrombotic or haemorrhagic events, six splenectomies, two abortions) and a very enlarged spleen in half the cases. However, after the initial complications, the overall survival is very long (exceeding 70%, even when including the initial complications, at 15 years). The vascular accidents occur exclusively in the phlebotomized patients, the main risk factor being the poor stability of the haematocrit. Only one acute leukaemia was observed among the 14 cases treated by radioactive phosphorus and/or alkylating chemotherapy. The most frequent late complication was evolution towards myelofibrosis. This spent phase seemed to occur earlier in patients treated by phlebotomy. On the basis of this data, we would advise the following therapeutic strategy: phlebotomies, as soon as the diagnosis is established, and a systematic long-term treatment by hydroxyurea with the hope of reducing the number of vascular complications and of delaying the evolution towards the spent phase and the myelofibrosis.
在20多年间,对58例青年真性红细胞增多症患者(46例符合完整的PVSG标准,12例红细胞体积升高且白细胞增多或血小板增多,无脾肿大)进行了研究,并随访了3至24年。这些病例约占在此期间转诊至圣路易斯医院核医学科的真性红细胞增多症病例的5%。他们与老年患者在初始临床严重程度、首发症状与诊断之间的间隔时间短、常伴有危及生命的并发症(2例肝静脉血栓形成、6例血栓形成或出血事件、6例脾切除术、2例流产)以及半数病例脾脏非常肿大等方面有所不同。然而,在初始并发症之后,总体生存期很长(即使包括初始并发症,15年时超过70%)。血管意外仅发生在放血治疗的患者中,主要危险因素是血细胞比容稳定性差。在14例接受放射性磷和/或烷化化疗的患者中仅观察到1例急性白血病。最常见的晚期并发症是向骨髓纤维化演变。这种终末期似乎在接受放血治疗的患者中出现得更早。基于这些数据,我们建议采取以下治疗策略:一旦确诊即进行放血治疗,并采用羟基脲进行系统性长期治疗,以期减少血管并发症的数量,并延缓向终末期和骨髓纤维化的演变。